Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million indemnity holdback to Elutia with no claims, completing the $88 million BioEnvelope divestiture that closed October 1, 2025. Elutia says this is the third of three 2026 funding milestones, alongside the Avenue Capital loan facility (closed August 11) and SimpliDerm divestiture (closed August 17), and that it is now funded into 2029 without an equity offering.
Key figures
- Deal Value Usd
- 88000000
- Escrow payment
- 8000000
- Funding runway
- into 2029
- Target market size
- $1.5 billion
- Nxt41x fda decision expected
- first half of 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.